AI image of a lung cross section
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

4D Medical’s (ASX:4DX) radioisotope-free CT:VQ lung scanning tech will form part of a U.S. Department of Defense-paid pilot leading into a formal FDA submission for approval. The company sees the chance to “displace the one million nuclear VQ scans performed each year… a billion dollar opportunity.”

4D Medical, which specialises in lung scanning technology, has a long-running history with the US DoD including former studies around veterans who had received lung damage from ‘burn pits’ – which are what they sound like.

As for its CT:VQ product capability announced in December, 4DX had been working toward a ‘safer’ way of imaging lungs, with a $1.9M grant secured to that end.

Under the pilot program announced on Monday, the DoD will not work with veterans but instead with active military personnel. The value proposition here for 4DX, in terms of the sheer size of the U.S. military membership, is fairly obvious.

“With over 200 military hospitals and clinics globally, the [Military Health Service] is tasked with providing high-quality, integrated healthcare to ensure the readiness and resilience of the U.S. Armed Forces,” the company reiterated.

Though, for now, it’s still small scale. Greater fruits will likely be borne if the ‘commercial pilot’ is deemed by DoD (or MHS) as a success. A total of 80 patients will form part of the first trial.

Of likely interest is 4DX’s CT:VQ scans allow for early detection of multiple lung conditions including CPOD and chronic thromboembolic hypertension.

“We are honoured to receive continued interest in the use of our technology from the DoD as a new pathway to enhance lung health outcomes for military personnel,” 4DX CEO Andreas Fouras said.

“CT:VQ is set to disrupt a billion-dollar segment of respiratory diagnostics by displacing Nuclear VQ imaging with a technology that is faster, safer, cheaper, more convenient and more accessible. We have been working for some time, leveraging hard-fought experience with existing products, to build an aggressive market adoption strategy.”

4DX last traded at 49.5cps.

Join the discussion: See what HotCopper users are saying about 4D Medical and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

4DX by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: IT & Bank stocks lead index lower | January 13, 2025

The big banks, the market darlings throughout 2024, were sold off today. CBA shed 2.1%, NAB…
The Market Online Video

US economy and stock market outlook for 2025: Bullish vs. bearish predictions

This week on Money and Investing, Mitch Olarenshaw and I share insights into the 2025 outlook for the U.S. economy and stock market.
EU flag

Vulcan Energy’s comeback era charged up on EU-first lithium hydroxide yields

Vulcan Energy's comeback era is in full swing after reporting on Monday its first production of…
Mountain in Malawi

Sample work leaves Chilwa ‘pleasantly surprised’ on Malawai REE, niobium mineralisation

Chilwa Minerals Ltd has reported geochemical soil sampling results from 11 priority targets identified through a…